SpineOvations' DiscSeal study for low back pain completes enrollment — 3 insights

Alan Condon -   Print  |

SpineOvations on Feb 24. finished enrollment for its DiscSeal clinical study in patients suffering from lumbar pain.

Three insights:

1. A total of six patients were treated with DiscSeal, a viscous material injected percutaneously into the intervertebral diseased disc of patients under local anesthesia.

2. The product was administered to patients with low back pain caused by discogenic disease and who have not been sufficiently treated by first-line medical therapy.

3. The study aims to evaluate DiscSeal's safety and efficacy in reducing levels of pain from the patients' pre-treatment pain levels over a six-month period.

More articles on biologics:
Stryker ranks No. 8 in Fortune's 100 best workplaces
Wuhan neurosurgeon, hospital director dies from coronavirus, death toll rises to 1,800+
Medtronic reports spine revenue up 3%, hurt by low BMP sales: 7 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers